Metropolitan Life Insurance Company (MetLife)’s Cytek Biosciences CTKB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-6,522
| Closed | -$43.8K | – | 526 |
|
|
2024
Q1 | $43.8K | Sell |
6,522
-967
| -13% | -$6.49K | ﹤0.01% | 1476 |
|
|
2023
Q4 | $68.3K | Hold |
7,489
| – | – | ﹤0.01% | 1279 |
|
|
2023
Q3 | $41.3K | Buy |
7,489
+793
| +12% | +$4.38K | ﹤0.01% | 1514 |
|
|
2023
Q2 | $57.2K | Buy |
6,696
+405
| +6% | +$3.46K | ﹤0.01% | 1346 |
|
|
2023
Q1 | $57.8K | Sell |
6,291
-792
| -11% | -$7.28K | ﹤0.01% | 1311 |
|
|
2022
Q4 | $72.3K | Hold |
7,083
| – | – | ﹤0.01% | 1248 |
|
|
2022
Q3 | $104K | Hold |
7,083
| – | – | ﹤0.01% | 993 |
|
|
2022
Q2 | $76K | Buy |
7,083
+668
| +10% | +$7.17K | ﹤0.01% | 1229 |
|
|
2022
Q1 | $69.2K | Buy |
6,415
+1,536
| +31% | +$16.6K | ﹤0.01% | 1410 |
|
|
2021
Q4 | $79.6K | Hold |
4,879
| – | – | ﹤0.01% | 2593 |
|
|
2021
Q3 | $104K | Buy |
+4,879
| New | +$104K | ﹤0.01% | 2494 |
|